Incyte Genomics to Report Third Quarter 2002 Financial Results on November 12 PALO ALTO, CA, October 31, 2002 - Incyte Genomics, Inc. (Nasdaq: INCY), announced today that it will report third quarter fiscal year 2002 financial results on Tuesday, November 12, 2002 after the close of the stock market. Incyte's senior management will host a conference call on Tuesday, November 12, 2002 at 2:00 p.m. PST to discuss the company's third quarter 2002 financial results and recent activities. The domestic dial in number for the conference call will be 800-473-6123 and the international dial in number will be 973-582-2710. A replay of the conference call will be available through November 19, 2002 (12:00 midnight PST). The replay dial in number for both U.S. and International callers will be 973-341-3080 and the PIN number access code will be 3568672. A webcast will be distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel. Institutional investors can access the call via CCBN's password protected event management site, StreetEvents (www.streetevents.com). Incyte Genomics, Inc., has the largest commercial portfolio of issued United States patents covering human, full-length genes and the proteins they encode. Incyte is leveraging its leading intellectual property and genomic information position to be a leader in discovering and developing therapeutic small molecules, secreted proteins and antibodies. In addition, Incyte has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and licenses pharmaceutically relevant intellectual property. These offerings facilitate pharmaceutical and biotechnology researchers in their drug discovery and development; including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including without limitation statements as to the anticipated date of Incyte's financial results announcement; the ability of Incyte's products and services to enhance the research efforts of its customers and Incyte's ability to leverage its intellectual property position to become a leader in the discovery and development of therapeutic small molecules, secreted proteins and antibodies, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including scheduling conflicts; the impact of competition and alternative technologies, processes and approaches on Incyte's business; Incyte's ability to compete against competitors that may have greater financial or other resources; changes in consumer demand for Incyte's products and services; economic factors that may impact Incyte's business and product offerings; changes in Incyte's business plan; Incyte's ability to obtain patent protection for its discoveries and to continue to be effective in expanding its patent coverage; changes in patent laws; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the Quarter ended June 30, 2002. Incyte disclaims any intent or obligation to update these forward-looking statements.